论文部分内容阅读
肺结核病是由结核分枝杆菌引起的呼吸系统的传染病,人感染结核分枝杆菌后是否发病与免疫功能密切相关~([1])。近年来结核病有逐年上升的趋势,复治菌阳病例也相应增多,成为结核病治疗的难题之一。为提高复治涂阳肺结核病的治疗效果,我院自2010年1月至2012年1月应用胸腺肽联合抗结核药物治疗复治涂阳肺结核54例,取得较好的临床疗效,报告如下。
Tuberculosis is caused by the respiratory tract of Mycobacterium tuberculosis infection, human infection with Mycobacterium tuberculosis is closely related to the immune function and immune function (1). In recent years, there is a trend of increasing TB year by year. The cases of retreatment of bacilli also increase correspondingly, which has become one of the problems in tuberculosis treatment. In order to improve the therapeutic effect of smear-positive pulmonary tuberculosis in our hospital, our hospital from January 2010 to January 2012 application of thymosin combined with anti-tuberculosis drugs in the treatment of smear positive pulmonary tuberculosis in 54 cases achieved good clinical efficacy, the report is as follows.